drozitumab drozitumab drozitumab is a human monoclonal antibody in development for the treatment of cancers. it targets tumour necrosis factor related apoptosis-inducing ligand (trail), whose receptors are found on the surface of many types of malignant cells. drozitumab was developed by genentech. drozitumabmonoclonal antibodytypewhole antibodysourcehumantargetdr5clinical dataatc codenoneidentifierscas number912628-39-8 nchemspidernoneuniisq67484ma7keggd09888 nchemical and physical dataformulac6334h9792n1700o2000s42molar mass143104.43 g·mol−1 ny (what is this?) (verify) although drozitumab was studied in phase ii trials for treating chondrosarcoma, colorectal cancer, non-hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.